|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||10.33 - 10.33|
|52 Week Range||7.90 - 21.00|
|Beta (5Y Monthly)||0.33|
|PE Ratio (TTM)||9.52|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jun 03, 2021|
|1y Target Est||N/A|
Spanish pharmaceutical company Grifols reported a 30% drop in nine-month net profit on Tuesday, due in part to acquisition costs. Grifols said it was still on track to meet its full-year financial targets, but its shares fell 4.2% in morning trade. The company, which uses blood plasma to make medicines, saw its business severely hit by the pandemic as blood collection was halted in many countries.
Spanish pharma group Grifols said on Friday a lawsuit filed in the United States by blood donors who claim the company violated their privacy would have no material impact, after a report in newspaper El Economista sent the shares sharply lower. The company said about 54,000 donors in Illinois had filed a lawsuit claiming Grifols breached data protection regulations, confirming the newspaper report. Grifols shares were down 5.3% on Friday morning, briefly the worst performer on the blue-chip Ibex-35 index, which was down 2.1%.
Grifols appointed an executive chairman on Monday, as the Spanish pharmaceutical company strives to recover from a pandemic-related hit and a 49% drop in its shares so far this year. Steven F. Mayer, an independent board member since 2011 and a former senior managing director of Cerberus Global Private Equity, will become executive chairman, effective immediately. The company's outgoing non-executive chairman, Victor Grifols Roura, who was chief executive from 1987 to 2016, has been named honorary chairman.